Skin manifestations of COVID-19 in children: Part 2

D Andina 1, A Belloni-Fortina 2, C Bodemer 3, E Bonifazi 4, A Chiriac 5, I Colmenero 6, A Diociaiuti 7, M El-Hachem 7, L Fertitta 3, D van Gysel 8, A Hernández-Martín 1, T Hubiche 9, C Luca 5, L Martos-Cabrera 1, A Maruani 10, F Mazzotta 4, A D Akkaya 11, M Casals 12, J Ferrando 13, R Grimalt 14, I Grozdev 15, V Kinsler 16, M A Morren 17, M Munisami 18, A Nanda 19, M P Novoa 20, H Ott 21, S Pasmans 22, C Salavastru 23, V Zawar 24, A Torrelo 1; ESPD Group for the Skin Manifestations of COVID-19

Affiliations

01 April 2021

-

doi: 10.1111/ced.14482

Abstract

The current COVID-19 pandemic is caused by the SARS-CoV-2 coronavirus. The initial recognized symptoms were respiratory, sometimes culminating in severe respiratory distress requiring ventilation, and causing death in a percentage of those infected. As time has passed, other symptoms have been recognized. The initial reports of cutaneous manifestations were from Italian dermatologists, probably because Italy was the first European country to be heavily affected by the pandemic. The overall clinical presentation, course and outcome of SARS-CoV-2 infection in children differ from those in adults, as do the cutaneous manifestations of childhood. In this review, we summarize the current knowledge on the cutaneous manifestations of COVID-19 in children after thorough and critical review of articles published in the literature and from the personal experience of a large panel of paediatric dermatologists in Europe. In Part 1, we discussed one of the first and most widespread cutaneous manifestations of COVID-19, chilblain-like lesions. In this part of the review, we describe other manifestations, including erythema multiforme, urticaria and Kawasaki disease-like inflammatory multisystemic syndrome. In Part 3, we discuss the histological findings of COVID-19 manifestations, and the testing and management of infected children for both COVID-19 and any other pre-existing conditions.
 

Figures

Figure 1 (a,b) Typical targetand targetoid lesions in COVID‐19‐related erythema multiforme.

Figure 1 (a,b) Typical targetand targetoid lesions in COVID‐19‐related erythema multiforme.

Figure 2 Urticaria in a child with COVID‐19.

Figure 2 Urticaria in a child with COVID‐19.

Figure 3 Vesicular exanthem of COVID‐19.

Figure 3 Vesicular exanthem of COVID‐19.

Figure 4 (a,b) Erythmatous exanthem in paediatric inflammatory multisystem syndrome.

Figure 4 (a,b) Erythmatous exanthem in paediatric inflammatory multisystem syndrome.

Figure 5 Purpuric rash in a child with suspected COVID‐19.

Figure 5 Purpuric rash in a child with suspected COVID‐19.

Figure 6 Maculopapular exanthemin COVID‐19.

Figure 6 Maculopapular exanthemin COVID‐19.

Figure 7 (a,b) Pityriasis rosea‐like eruption intwo childrenwith suspected COVID‐19.

Figure 7 (a,b) Pityriasis rosea‐like eruption intwo childrenwith suspected COVID‐19.

Similar articles

Skin manifestations of COVID-19 in children: Part 3.

Andina D, Belloni-Fortina A, Bodemer C, Bonifazi E, Chiriac A, Colmenero I, Diociaiuti A, El-Hachem M, Fertitta L, van Gysel D, Hernández-Martín A, Hubiche T, Luca C, Martos-Cabrera L, Maruani A, Mazzotta F, Akkaya AD, Casals M, Ferrando J, Grimalt R, Grozdev I, Kinsler V, Morren MA, Munisami M, Nanda A, Novoa MP, Ott H, Pasmans S, Salavastru C, Zawar V, Torrelo A; ESPD Group for the Skin Manifestations of COVID-19.Clin Exp Dermatol. 2021 Apr;46(3):462-472. doi: 10.1111/ced.14483. Epub 2020 Nov 18.PMID: 33207021 Free PMC article. Review.

Skin manifestations of COVID-19 in children: Part 1.

Andina D, Belloni-Fortina A, Bodemer C, Bonifazi E, Chiriac A, Colmenero I, Diociaiuti A, El-Hachem M, Fertitta L, van Gysel D, Hernández-Martín A, Hubiche T, Luca C, Martos-Cabrera L, Maruani A, Mazzotta F, Akkaya AD, Casals M, Ferrando J, Grimalt R, Grozdev I, Kinsler V, Morren MA, Munisami M, Nanda A, Novoa MP, Ott H, Pasmans S, Salavastru C, Zawar V, Torrelo A; ESPD Group for the Skin Manifestations of COVID-19.Clin Exp Dermatol. 2021 Apr;46(3):444-450. doi: 10.1111/ced.14481. Epub 2020 Nov 12.PMID: 33180982 Free PMC article. Review.

Clinicopathologic correlations of COVID-19-related cutaneous manifestations with special emphasis on histopathologic patterns.

Rongioletti F, Ferreli C, Sena P, Caputo V, Atzori L.Clin Dermatol. 2021 Jan-Feb;39(1):149-162. doi: 10.1016/j.clindermatol.2020.12.004. Epub 2020 Dec 14.PMID: 33972045 Free PMC article. Review.

Skin Manifestations Associated with COVID-19: Current Knowledge and Future Perspectives.

Genovese G, Moltrasio C, Berti E, Marzano AV.Dermatology. 2021;237(1):1-12. doi: 10.1159/000512932. Epub 2020 Nov 24.PMID: 33232965 Free PMC article. Review.

Cutaneous manifestations of COVID-19.

Wang CJ, Worswick S.Dermatol Online J. 2021 Jan 15;27(1):13030/qt2m54r7nv.PMID: 33560783 Review.

Cited by

Perinatal/maternal-fetal-infant dermatologic manifestations of SARS-CoV-2. An Overview and Implications for diagnosis, treatment, and prognosis.

Young EM.Front Pediatr. 2022 Dec 2;10:1071839. doi: 10.3389/fped.2022.1071839. eCollection 2022.PMID: 36533244 Free PMC article. Review.

Skin, mucosa and nail findings in hospitalized pediatric patients with Coronavirus disease-2019 (COVID-19).

Özen T, Kahraman FC, Öcal S, Ovalı HF.An Bras Dermatol. 2023 Mar-Apr;98(2):208-215. doi: 10.1016/j.abd.2022.03.006. Epub 2022 Nov 23.PMID: 36435635 Free PMC article.

Clinicopathological Features of Cutaneous Findings of SARS-CoV-2 Infection.

Cobanoglu B, Cebeci F, Simsek M, Ozkanli S.Medeni Med J. 2022 Sep 21;37(3):270-276. doi: 10.4274/MMJ.galenos.2022.05046.PMID: 36128840 Free PMC article.

Epidemiology and clinical evolution of non-multisystem inflammatory syndrome (MIS-C) dermatological lesions in pediatric patients affected by SARS-CoV-2 infection: A systematic review of the literature.

Dondi A, Sperti G, Gori D, Guaraldi F, Montalti M, Parini L, Piraccini BM, Lanari M, Neri I.Eur J Pediatr. 2022 Oct;181(10):3577-3593. doi: 10.1007/s00431-022-04585-7. Epub 2022 Aug 10.PMID: 35948654 Free PMC article. Review.

Evolving Skin Rash as a Rare Cutaneous Manifestation in a Pediatric Patient With COVID-19 Infection.

Tilak K, Joung K, Apath M.Cureus. 2022 Jun 30;14(6):e26477. doi: 10.7759/cureus.26477. eCollection 2022 Jun.PMID: 35919370 Free PMC article.

KMEL References

https://pubmed.ncbi.nlm.nih.gov/

References

  1.  
    1. Grünwald P, Mockenhaupt M, Panzer R, Emmert S. Erythema multiforme, Stevens‐Johnson syndrome/toxic epidermal necrolysis – diagnosis and treatment. J Dtsch Dermatol Ges 2020; 18: 547–53. - PubMed
  2.  
    1. French LE, Prins C. Erythema multiforme, Stevens‐Johnson syndrome and toxic epidermal necrolysis. In: Dermatology, 3rd edn (Bolognia JL, Jorizzo JL, Schaffer JV, ed). Atlanta: Elsevier Saunders, 2012; 319–33.
  3.  
    1. Siedner‐Weintraub Y, Gross I, David A et al. Paediatric erythema multiforme: epidemiological, clinical and laboratory characteristics. Acta Derm Venereol 2017; 97: 489–92. - PubMed
  4.  
    1. Sokumbi O, Wetter DA. Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist. Int J Dermatol 2012; 51: 889–902. - PubMed
  5.  
    1. Galván Casas C, Català A, Carretero Hernández G et al. Classification of the cutaneous manifestations of COVID‐19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol 2020; 183: 71–7. - PMC - PubMed
  6.  
    1. Jimenez‐Cauhe J, Ortega‐Quijano D, Carretero‐Barrio I et al. Erythema multiforme‐like eruption in patients with COVID‐19 infection: clinical and histological findings. Clin Exp Dermatol 2020; 45: 892–5. 10.1111/ced.14281 - DOI - PMC - PubMed
  7.  
    1. Janah H, Zinebi A, Elbenaye J. Atypical erythema multiforme palmar plaques lesions due to SARS‐CoV‐2. J Eur Acad Dermatol Venereol 2020; 34: e373–5. - PMC - PubMed
  8.  
    1. Torrelo A, Andina D, Santonja C et al. Erythema multiforme‐like lesions in children and COVID‐19. Pediatr Dermatol 2020; 37: 442–6. - PMC - PubMed
  9.  
    1. Labé P, Ly A, Sin C et al. Erythema multiforme and Kawasaki disease associated with COVID‐19 infection in children. J Eur Acad Dermatol Venereol 2020; 34: e539–41. 10.1111/jdv.16666 - DOI - PMC - PubMed
  10.  
    1. García‐Gil MF, García García M, Monte Serrano J et al. Acral purpuric lesions (erythema multiforme type) associated with thrombotic vasculopathy in a child during the COVID‐19 pandemic. J Eur Acad Dermatol Venereol 2020; 34. 10.1111/jdv.16644 - DOI - PMC - PubMed
  11.  
    1. Imbalzano E, Casciaro M, Quartuccio S et al. Association between urticaria and virus infections: a systematic review. Allergy Asthma Proc 2016; 37: 18–22. - PubMed
  12.  
    1. Sachdeva M, Gianotti R, Shah M et al. Cutaneous manifestations of COVID‐19: report of three cases and a review of literature. J Dermatol Sci 2020; 98: 75–81. - PMC - PubMed
  13.  
    1. Fernandez‐Nieto D, Ortega‐Quijano D, Segurado‐Miravalles G et al. Comment on: Cutaneous manifestations in COVID‐19: a first perspective. Safety concerns of clinical images and skin biopsies. J Eur Acad Dermatol Venereol 2020; 34: e252–4. - PMC - PubMed
  14.  
    1. Rodriguez‐Jimenez P, Chicharro P, De Argila D et al. Urticaria‐like lesions in COVID‐19 patients are not really urticaria – a case with clinicopathologic correlation. J Eur Acad Dermatol Venereol 2020; 42: 564–70. 10.1111/jdv.16618 - DOI - PMC - PubMed
  15.  
    1. Gunawan C, Angela A, Widysanto A. Urticarial eruption in coronavirus disease 2019 (COVID‐19) infection: a case report in Tangerang. Indonesia. J Eur Acad Dermatol Venereol 2020; 34: e372–3. - PMC - PubMed
  16.  
    1. Zhang JJ, Dong X, Cao YY et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy 2020; 75: 1730–41. - PubMed
  17.  
    1. Henry D, Ackerman M, Sancelme E et al. Urticarial eruption in COVID‐19 infection. J Eur Acad Dermatol Venereol 2020; 34: e244–5. - PMC - PubMed
  18.  
    1. Aktas H, Hamidi AA. Urticaria in a patient with COVID‐19: therapeutic and diagnostic difficulties. Dermatol Ther 2020; e13610. 10.1111/dth.13610 - DOI - PubMed
  19.  
    1. de Medeiros VLS, Silva LFT. Follow‐up of skin lesions during the evolution of COVID‐19: a case report. Arch Dermatol Res 2020; 1–4. 10.1007/s00403-020-02091-0 - DOI - PMC - PubMed
  20.  
    1. Naziroglu T, Sozen S, Ozkan P et al. A case of COVID‐19 pneumonia presenting with acute urticaria. Dermatol Ther 2020; e13575. 10.1111/dth.13575 - DOI - PMC - PubMed
  21.  
    1. Damme C, Berlingin E, Saussez S, Accaputo O. Acute urticaria with pyrexia as the first manifestations of a COVID‐19 infection. J Eur Acad Dermatol Venereol 2020; 334: e300–1. - PMC - PubMed
  22.  
    1. Estebanez A, Perez‐Santiago L, Silva E et al. Cutaneous manifestations in COVID‐19: a new contribution. J Eur Acad Dermatol Venereol 2020; 34: e250–1. - PMC - PubMed
  23.  
    1. Hedou M, Carsuzaa F, Chary E et al. Comment on "Cutaneous manifestations in COVID‐19: a first perspective" by Recalcati S. J Eur Acad Dermatol Venereol 2020; 34: e299–300. - PMC - PubMed
  24.  
    1. Morey‐Olive M, Espiau M, Mercadal‐Hally M et al. Cutaneous manifestations in the current pandemic of coronavirus infection disease (COVID 2019). An Pediatr (Engl Ed) 2020; 92: 374–5. - PMC - PubMed
  25.  
    1. Young S, Fernandez AP. Skin manifestations of COVID‐19. Cleve Clin J Med 2020. 10.3949/ccjm.87a.ccc031 - DOI - PubMed
  26.  
    1. Masson de A, Bouaziz JD, Sulimovic L et al. Chilblains are a common cutaneous finding during the COVID‐19 pandemic: a retrospective nationwide study from France. J Am Acad Dermatol 2020; 83: 667–70. - PMC - PubMed
  27.  
    1. Gisondi P, PIaserico S, Bordin C et al. Cutaneous manifestations of SARS‐CoV‐2 infection: a clinical update. J Eur Acad Dermatol Venereol 2020. 10.1111/jdv.16774 - DOI - PMC - PubMed
  28.  
    1. Marzano AV, Genovese G, Fabbrocini G et al. Varicella‐like exanthema as a specific COVID‐19‐associated skin manifestation: multi‐center case series of 22 patients. J Am Acad Dermatol 2020; 83: 280–5. - PMC - PubMed
  29.  
    1. De Giorgi V, Recalcati S, Jia Z et al. Cutaneous manifestations related to coronavirus disease 2019 (COVID‐19): a prospective study from China and Italy. J Am Acad Dermatol 2020; 83: 674–5. - PMC - PubMed
  30.  
    1. Fernandez‐Nieto D, Ortega‐Quijano D, Jimenez‐Cauhe J et al. Clinical and histological characterization of vesicular COVID‐19 rashes: a prospective study in a tertiary care hospital. Clin Exp Dermatol 2020; 45: 872–5. 10.1111/ced.14277 - DOI - PMC - PubMed
  31.  
    1. Marzano AV, Genovese G. Response to “Reply to ‘Varicella‐like exanthem as a specific COVID‐19‐associated skin manifestation: multicenter case series of 22 patients’: To consider varicella‐like exanthem associated with COVID‐19, virus varicella zoster and virus herpes simplex must be ruled out”. J Am Acad Dermatol 2020; 83: e255–6. - PMC - PubMed
  32.  
    1. Tang K, Wang Y, Zhang H et al. Cutaneous manifestations of the Coronavirus Disease 2019 (COVID‐19): a brief review. Dermatol Ther 2020; e13528. 10.1111/dth.13528 - DOI - PMC - PubMed
  33.  
    1. Gianotti R, Veraldi S, Recalcati S et al. Cutaneous clinico‐pathological findings in three COVID‐19‐positive patients observed in the metropolitan area of Milan, Italy. Acta Derm Venereol 2020; 100: adv00124. - PubMed
  34.  
    1. Genovese G, Colonna C, Marzano AV. Varicella‐like exanthem associated with COVID‐19 in an 8‐year‐old girl: a diagnostic clue? Pediatr Dermatol 2020; 37: 435–6. - PMC - PubMed
  35.  
    1. Piccolo V, Neri I, Filippeschi C et al. Chilblain‐like lesions during COVID‐19 epidemic: a preliminary study on 63 patients. J Eur Acad Dermatol Venereol 2020; 34: e29–3. - PMC - PubMed
  36.  
    1. Wollina U, Karadağ AS, Rowland‐Payne C et al. Cutaneous signs in COVID‐19 patients: a review. Dermatol Ther 2020; e13549. - PMC - PubMed
  37.  
    1. Mahé A, Birckel A, Merklen C et al. Histology of skin lesions establishes that the vesicular rash associated with COVID‐19 is not ‘varicella‐like’. J Eur Acad Dermatol Venereol 2020; 34: e559––61.. 10.1111/jdv.16706 - DOI - PMC - PubMed
  38.  
    1. Mahe A, Birckel E, Krieger S et al. A distinctive skin rash associated with coronavirus disease 2019. J Eur Acad Dermatol Venereol 2020; 34: e246–7. - PMC - PubMed
  39.  
    1. Schnabel A, Hedrich CM. Childhood vasculitis. Front Pediatr 2018; 6: 421. - PMC - PubMed
  40.  
    1. Makino N, Nakamura Y, Yashiro M et al. Nationwide epidemiologic survey of Kawasaki disease in Japan, 2015–16. Pediatr Int Off J Jpn Pediatr Soc 2019; 61: 397–403. - PubMed
  41.  
    1. Esper F, Shapiro ED, Weibel C et al. Association between a novel human coronavirus and Kawasaki disease. J Infect Dis 2005; 191: 499–502. - PMC - PubMed
  42.  
    1. Esper F, Weibel C, Ferguson D et al. Evidence of a novel human coronavirus that is associated with respiratory tract disease in infants and young children. J Infect Dis 2005; 191: 492–8. - PMC - PubMed
  43.  
    1. Chang L‐Y, Lu C‐Y, Shao P‐L et al. Viral infections associated with Kawasaki disease. J Formos Med Assoc Taiwan Yi Zhi 2014; 113: 148–54. - PMC - PubMed
  44.  
    1. Dong Y, Mo X, Hu Y et al. Epidemiology of COVID‐19 among children in China. Pediatrics 2020; 145: e20200702. - PubMed
  45.  
    1. Riphagen S, Gomez X, Gonzalez‐Martinez C et al. Hyperinflammatory shock in children during COVID‐19 pandemic. Lancet (Lond) Engl 2020; 39: 1607–8. - PMC - PubMed
  46.  
    1. Cabrero‐Hernández M, García‐Salido A, Leoz‐Gordillo I et al. Severe SARS‐CoV‐2 infection in children with suspected acute abdomen: a case series from a tertiary hospital in Spain. Pediatr Infect Dis J 2020; 39: e195–8. - PubMed
  47.  
    1. Verdoni L, Mazza A, Gervasoni A et al. An outbreak of severe Kawasaki‐like disease at the Italian epicentre of the SARS‐CoV‐2 epidemic: an observational cohort study. Lancet (Lond) Engl 2020; 395: 1771–8. - PMC - PubMed
  48.  
    1. Toubiana J, Poirault C, Corsia A et al. Kawasaki‐like multisystem inflammatory syndrome in children during the covid‐19 pandemic in Paris, France: prospective observational study. BMJ 2020; 369: m2094. - PMC - PubMed
  49.  
    1. Trouillet‐Assant S, Viel S, Gaymard A et al. Type I IFN immunoprofiling in COVID‐19 patients. J Allergy Clin Immunol 2020; 146: 206–8.e2. - PMC - PubMed
  50.  
    1. ECDC. Paediatric inflammatory multisystem syndrome and SARSCoV‐ 2 infection in children, 2020. Available at: https://www.ecdc.europa.eu/sites/default/files/documents/covid‐19‐riskas... (accessed 15 May 2020).
  51.  
    1. CDC. Multisystem inflammatory syndrome in children (MIS‐C) associated with coronavirus disease 2019 (COVID‐19), 2020. Available at: https://emergency.cdc.gov/han/2020/han00432.asp (accessed 14 May 2020).
  52.  
    1. Jones VG, Mills M, Suarez D et al. COVID‐19 and Kawasaki disease: novel virus and novel case. Hosp Pediatr 2020; 10: 537–40. - PubMed
  53.  
    1. Licciardi F, Pruccoli G, Denina M et al. SARS‐CoV‐2‐Induced Kawasaki‐like hyperinflammatory syndrome: a novel COVID phenotype in children. Pediatrics 2020; 146: e20201711. - PubMed
  54.  
    1. Yancy CW. COVID‐19 and African Americans. JAMA 2020; 323: 1891–2. - PubMed
  55.  
    1. Giudicessi JR, Roden DM, Wild A, Ackerman MJ. Genetic susceptibility for COVID‐19‐associated sudden cardiac death in African Americans. Heart Rhythm 2020; 17: 1487–92. - PMC - PubMed
  56.  
    1. Oualha M, Bendavid M, Berteloot L et al. Severe and fatal forms of COVID‐19 in children. Arch Pediatr 2020; 27: 235–8. - PMC - PubMed
  57.  
    1. McCrindle BW, Rowley AH, Newburger JW. et al. Diagnosis, treatment, and long‐term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation 2017; 135: e927–99. - PubMed
  58.  
    1. Grimaud M, Starck J, Levy M et al. Acute myocarditis and multisystem inflammatory emerging disease following SARS‐CoV‐2 infection in critically ill children. Ann Intensive Care 2020; 10: 69. - PMC - PubMed
  59.  
    1. Li Y, Zheng Q, Zou L et al. Kawasaki disease shock syndrome: clinical characteristics and possible use of IL‐6, IL‐10 and IFN‐γ as biomarkers for early recognition. Pediatr Rheumatol Online J 2019; 17: 1. - PMC - PubMed
  60.  
    1. Mehta P, McAuley DF, Brown M et al. COVID‐19: consider cytokine storm syndromes and immunosuppression. Lancet (Lond) Engl 2020; 395: 1033–4. - PMC - PubMed
  61.  
    1. Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506. - PMC - PubMed
  62.  
    1. Turnier JL, Anderson MS, Heizer HR et al. Concurrent respiratory viruses and Kawasaki disease. Pediatrics 2015; 136: 609–14. - PubMed
  63.  
    1. Shirato K, Imada Y, Kawase M et al. Possible involvement of infection with human coronavirus 229E, but not NL63, in Kawasaki disease. J Med Virol 2014; 86: 2146–53. - PMC - PubMed
  64.  
    1. Ebihara T, Endo R, Ma X et al. Lack of association between New Haven coronavirus and Kawasaki disease. J Infect Dis 2005; 19: 351–2. - PMC - PubMed
  65.  
    1. Schroeder AR, Wilson KM, Ralston SL. COVID‐19 and Kawasaki disease: finding the signal in the noise. Hosp Pediatr 2020; 10: e1–3. 10.1542/hpeds.2020-000356 - DOI - PubMed
  66.  
    1. Kanegaye JT, Wilder MS, Molkara D et al. Recognition of a Kawasaki disease shock syndrome. Pediatrics 2009; 123: 783–9. - PMC - PubMed
  67.  
    1. Zulfiqar AA, Lorenzo‐Villalba N, Hassler P, Andrès E. Immune thrombocytopenic purpura in a patient with Covid‐19. N Engl J Med 2020; 382: e43. - PMC - PubMed
  68.  
    1. Joob B, Wiwanitkit V. COVID‐19 can present with a rash and be mistaken for Dengue. J Am Acad Dermatol 2020; 82: e17. - PMC - PubMed
  69.  
    1. Jimenez‐Cauhe J, Ortega‐Quijano D, Prieto‐Barrios M et al. Reply to "COVID‐19 can present with a rash and be mistaken for Dengue": Petechial rash in a patient with COVID‐19 infection. J Am Acad Dermatol 2020; 8: e141–2. - PMC - PubMed
  70.  
    1. Zhang Y, Cao W, Xiao M et al. Clinical and coagulation characteristics of 7 patients with critical COVID‐2019 pneumonia and acro‐ischemia. Zhonghua Xue Ye Xue Za Zhi 2020; 41: E006. - PubMed
  71.  
    1. Bouaziz JD, Duong T, Jachiet M et al. Vascular skin symptoms in COVID‐19: a French observational study. J Eur Acad Dermatol Venereol 2020; 34. 10.1111/jdv.16544. - DOI - PMC - PubMed
  72.  
    1. Olisova OY, Anpilogova EM, Shnakhova LM. Cutaneous manifestations in COVID‐19: a skin rash in a child. Dermatol Ther 2020; e13712. 10.1111/dth.13712 - DOI - PMC - PubMed
  73.  
    1. Kamali Aghdam M, Jafari N, Eftekhari K. Novel coronavirus in a 15‐day‐old neonate with clinical signs of sepsis, a case report. Infect Dis (Lond) 2020; 183: 591–3. - PMC - PubMed
  74.  
    1. Kang JH. Febrile illness with skin rashes. Infect Chemother 2015; 47: 155–66. - PMC - PubMed
  75.  
    1. Llamas‐Velasco M, Muñoz‐Hernández P, Lázaro‐González J et al. Thrombotic occlusive vasculopathy in skin biopsy from a livedoid lesion of a COVID‐19 patient. Br J Dermatol 2020; 183: 591–3. 10.1111/bjd.19222 - DOI - PMC - PubMed
  76.  
    1. Diaz‐Guimaraens B, Dominguez‐Santas M, Suarez‐Valle A et al. Petechial skin rash associated with severe acute respiratory syndrome coronavirus 2 infection. JAMA Dermatol 2020; 156: 820. 10.1001/jamadermatol.2020.1741 - DOI - PubMed
  77.  
    1. Recalcati S. Cutaneous manifestations in COVID‐19: a first perspective. J Eur Acad Dermatol Venereol 2020; 34: e212–13. - PubMed
  78.  
    1. Herrero‐Moyano M, Capusan TM, Andreu‐Barasoain M et al. A clinicopathological study of 8 patients with COVID‐19 pneumonia and a late‐onset exanthema. J Eur Acad Dermatol Venereol 2020. 10.1111/jdv.16631 - DOI - PMC - PubMed
  79.  
    1. Reymundo A, Fernáldez‐Bernáldez A, Reolid A et al. Clinical and histological characterization of late appearance maculopapular eruptions in association with the coronavirus disease 2019. A case series of seven patients. J Eur Acad Dermatol Venereol 2020: 10.1111/jdv.16707 - DOI - PMC - PubMed
  80.  
    1. Delaleu J, Deniau B, Battistella M et al. Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID‐19. J Allergy Clin Immunol Pract 2020; 8: 2777–9.e1. 10.1016/j.jaip.2020.05.046 - DOI - PMC - PubMed
  81.  
    1. Ehsani AH, Nasimi M, Bigdelo Z. Pityriasis rosea as a cutaneous manifestation of COVID‐19 infection. J Eur Acad Dermatol Venereol 2020; 34. 10.1111/jdv.16579 - DOI - PMC - PubMed
  82.  
    1. Dursun R, Temiz SA. The clinics of HHV‐6 infection in COVID‐19 pandemic: pityriasis rosea and Kawasaki disease. Dermatol Ther 2020; e13730. 10.1111/dth.13730 - DOI - PMC - PubMed
  83.  
    1. Nuno‐Gonzalez A, Martin‐Carrillo P, Magaletsky K, et al. Prevalence of mucocutaneous manifestations, oral and palmoplantar findings in 666 patients with COVID‐19 in a field hospital in Spain. Br J Dermatol. 2020;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537506/pdf/BJD‐9999‐na.pdf - PMC - PubMed
  84.  
    1. Tartari F, Spadotto A, Zengarini C et al. Herpes zoster in COVID‐19‐positive patients. Int J Dermatol 2020; 59: 1028–9. - PMC - PubMed
  85.  
    1. Llamas‐Velasco M, Rodríguez‐Jiménez P, Chicharro P et al. Reply to "Varicella‐like exanthem as a specific COVID‐19‐associated skin manifestation: multicenter case series of 22 patients": To consider varicella‐like exanthem associated with COVID‐19, virus varicella zoster and virus herpes simplex must be ruled out. J Am Acad Dermatol 2020; 83: e253–4. - PMC - PubMed

Page Navigation